When UK researchers are building a laboratory programme around recovery research peptides, two compounds appear more frequently than any other in the scientific literature: the TB-500 10mg research peptide and the BPC-157 10mg research peptide. Both sit within the Recovery Research Peptide category, both are widely studied across cellular biology and tissue-related research models, and both are available from Ascend Peptides UK with same-day dispatch and independently verified Certificates of Analysis from Janoshik.
But despite sharing a category label, the TB-500 10mg research peptide and the BPC-157 10mg research peptide are mechanistically distinct compounds. They operate through entirely different molecular pathways, have been studied in different experimental contexts, and are appropriate for different research objectives. Selecting between them or deciding whether both are needed requires a clear understanding of what each compound actually studies at the molecular level in Laboratory models.
This guide provides exactly that: a complete scientific comparison of the TB-500 10mg research peptide and the BPC-157 10mg research peptide, written specifically for UK-based researchers and laboratory professionals. For individual compound guides, see our dedicated TB-500 10mg research peptide guide and BPC-157 10mg research peptide guide. All content relates strictly to laboratory research. Both compounds are supplied for scientific research use only — not for human consumption, veterinary, or clinical application.
What are the TB-500 10mg and BPC-157 10mg Research Peptides?
Understanding what each compound is at the molecular level is the essential starting point for any meaningful comparison. These are not different formulations of the same molecule; they are structurally unrelated peptides derived from entirely different source proteins, with different amino acid chain lengths, molecular weights, and mechanisms.
The TB-500 10mg Research Peptide
The TB-500 10mg research peptide is a synthetic heptapeptide, seven amino acids in length, with the sequence Ac-LKKTETQ. It corresponds to amino acids 17 through 23 of Thymosin Beta-4, a naturally occurring 43-amino acid protein encoded by the TMSB4X gene.
This specific region represents the actin-binding domain of Thymosin Beta-4, which is the structural basis for TB-500’s primary laboratory activity as studied in cell models: binding to globular actin (G-actin) and modulating the balance between monomeric and filamentous actin in cell models. With a molecular weight of 889.02 g/mol and molecular formula C38H68N10O14, the TB-500 10mg research peptide is the smaller of the two compounds and is primarily used in studies examining cytoskeletal dynamics, cell migration, and extracellular matrix interactions.
The BPC-157 10mg Research Peptide
The BPC-157 10mg research peptide is a synthetic pentadecapeptide, fifteen amino acids in length, derived from a partial sequence of the body protection compound protein found in gastric juice. At a molecular weight of approximately 1,419.53 g/mol (C62H98N16O22), BPC-157 is substantially larger than TB-500.
Its primary documented mechanism in laboratory preclinical research involves the nitric oxide (NO) signalling system, specifically modulation of nitric oxide synthase (NOS) activity in vascular and tissue cell models.
Beyond the NO pathway, BPC-157 has been documented interacting with vascular endothelial growth factor (VEGF) signalling and epidermal growth factor (EGF) receptor pathways in preclinical models, making it a multi-pathway compound with a broader mechanistic footprint than the more targeted TB-500 10mg research peptide.
TB-500 10mg vs BPC-157 10mg Research Peptide: Molecular Comparison
|
Property |
TB-500 10mg Research Peptide |
BPC-157 10mg Research Peptide |
|---|---|---|
|
Full scientific name |
Thymosin Beta-4 Fragment(Ac-LKKTETQ) |
Body Protection Compound-157(pentadecapeptide) |
|
Amino acid length |
7 amino acids (heptapeptide) |
15 amino acids (pentadecapeptide) |
|
Molecular weight |
889.02 g/mol |
1,419.53 g/mol |
|
Molecular formula |
C38H68N10O14 |
C62H98N16O22 |
|
Peptide origin |
Thymosin Beta-4 — TMSB4X gene (AA 17–23) |
Gastric juice body protection compound |
|
Primary mechanism |
Actin-binding (G-actin sequestration) |
Nitric oxide pathway + VEGF + EGF receptor |
|
Research category |
Recovery Research Peptide |
Recovery Research Peptide |
|
SERP features (Google) |
Video, People Also Ask, Related searches |
Sitelinks, Video, Related searches, Discussions |
|
KD (keyword difficulty) |
KD 14 |
KD 17 |
|
WADA status |
Listed on WADA Prohibited List |
Listed on WADA Prohibited List |
|
Available from Ascend |
✓ TB-500 10mg — In Stock |
✓ BPC-157 10mg — In Stock |
The most critical distinction in this table for experimental design is the primary mechanism row. The TB-500 10mg research peptide operates through actin-binding and cytoskeletal modulation, a pathway entirely separate from the nitric oxide and growth factor signalling activity of the BPC-157 10mg research peptide.
These two compounds are not interchangeable. Results from studies using one cannot be used to predict the behaviour of the other in the same experimental system, and protocols designed for one will not produce valid data if the other is substituted.
Mechanisms of Action: How Each Research Peptide Works
How the TB-500 10mg Research Peptide Works
The TB-500 10mg research peptide acts primarily by binding to globular actin (G-actin), the monomeric form of actin, and sequestering it from polymerisation into filamentous actin (F-actin). This disruption of the actin monomer-polymer equilibrium has measurable downstream effects on cytoskeletal organisation, cell shape, mechanical stiffness, and directed motility in laboratory cell models.
Published research using scratch assays and transwell migration models has examined how this actin modulation influences directed cell movement and chemotaxis. Separately, the foundational research by Malinda et al. using rodent models established a relationship between Thymosin Beta-4 administration and collagen fibre organisation, which underpins much of the interest in the TB-500 fragment for tissue biology research.
TB-500 has also been studied in the context of inflammatory signalling, with experimental models examining its relationship to NF-κB pathway activity and pro-inflammatory cytokine release in in vitro systems.
How the BPC-157 10mg Research Peptide Works
The BPC-157 10mg research peptide operates through a mechanistically distinct axis. Its primary documented activity involves the nitric oxide (NO) signalling pathway, specifically its influence on nitric oxide synthase (NOS) activity in vascular and tissue cell models.
Nitric oxide is a critical signalling molecule involved in vasodilation, angiogenic responses, and inflammatory regulation. Beyond NOS, BPC-157 has been documented in published research interacting with VEGF signalling, the primary driver of new blood vessel formation in angiogenesis research models and with EGF receptor pathways that regulate cell proliferation and survival.
An important additional context unique to BPC-157 is its gastric origin: a substantial body of preclinical research has examined this compound specifically in gut biology models, stomach mucosal cell research, and gastrointestinal tissue models, an area where the TB-500 10mg research peptide has essentially no published research presence.
Research Applications: Where Each Peptide Is Most Studied
|
Research Area |
TB-500 10mg |
BPC-157 10mg |
|---|---|---|
|
Actin dynamics / cytoskeletal biology |
✓✓ Primary application |
✗ Not applicable |
|
Cell migration + motility assays |
✓✓ Extensively documented |
✓ Some evidence |
|
Nitric oxide (NO) signalling pathway |
✗ Not the primary mechanism |
✓✓ Primary application |
|
Angiogenesis + vascular cell models |
✓ Published evidence |
✓ Published evidence |
|
Wound biology + wound closure assays |
✓✓ Foundational literature |
✓✓ Foundational literature |
|
Inflammatory signalling (NF-κB, cytokines) |
✓ NF-κB pathway studies |
✓✓ Multiple cytokine studies |
|
Tendon and ligament cell models |
✓ Some published data |
✓✓ Well documented |
|
Gut and gastric mucosal biology |
✗ No published evidence |
✓✓ Gastric origin — extensively studied |
|
Bone cell and osteoblast research |
✗ Limited evidence |
✓ Published evidence |
|
Neuroprotection / CNS models |
✓ Emerging literature |
✓ Emerging literature |
|
Collagen + ECM research |
✓✓ Documented in literature |
✓ Some evidence |
|
VEGF growth factor pathway |
✗ Not the primary mechanism |
✓✓ Documented interaction |
The research applications table reveals the most practically important implications of these two compounds’ different mechanisms. The TB-500 10mg research peptide is clearly the stronger tool for cytoskeletal biology, actin dynamics, and cell migration research.
The BPC-157 10mg research peptide is clearly the stronger tool for nitric oxide pathway research, gut biology, tendon cell models, and multi-pathway growth factor studies. In wound biology and angiogenesis research, the two overlapping areas, both compounds have documented preclinical literature, but through mechanistically different routes: TB-500 via cytoskeletal reorganisation, BPC-157 via NO and VEGF pathway activity.
Researchers working in skin biology and cellular remodelling who want to complement either compound with a copper-binding mechanism should also consider our GHK-CU 50mg research peptide, a mechanistically distinct skin research peptide that operates via copper chaperone activity and has extensive published evidence in collagen synthesis and ECM research.
Which Research Peptide Should You Choose?
The answer depends entirely on what your research protocol is designed to investigate. There is no universally superior compound between the TB-500 10mg research peptide and the BPC-157 10mg research peptide; only the compound that is mechanistically aligned with your experimental objective.
|
Choose TB-500 10mg when… |
Choose BPC-157 10mg when… |
|---|---|
|
Your protocol focuses on actin dynamics and cytoskeletal remodelling |
Your protocol focuses on nitric oxide signalling pathways |
|
Studying directed cell migration, chemotaxis, or scratch assays |
Studying gut biology, gastric mucosal cell models or stomach-derived compounds |
|
Investigating Thymosin Beta-4 fragment activity specifically |
Investigating tendon cell biology or ligament-related cell models |
|
Running wound closure assays where actin modulation is the variable |
Studying VEGF or EGF receptor pathway contributions to cellular behaviour |
|
Research requires a 7-amino acid actin-binding molecular probe |
Research requires a 15-amino acid NO-pathway molecular probe |
|
Examining extracellular matrix dynamics via the cytoskeletal route |
Examining bone cell or osteoblast research models |
For researchers whose experimental design genuinely requires investigation of both actin-mediated cytoskeletal dynamics and nitric oxide pathway activity simultaneously for example, in a study examining how both mechanisms contribute to cellular behaviour in a wound biology model, both the TB-500 10mg research peptide and the BPC-157 10mg research peptide can be incorporated as independent variables within the same protocol.
In this case, both should be sourced to the same purity specification (≥98% HPLC-verified), reconstituted in the same solvent, and stored under identical conditions to minimise confounding variables between compound arms.
Storage, Reconstitution and Handling — Both Compounds
Both the TB-500 10mg research peptide and the BPC-157 10mg research peptide are supplied by Ascend Peptides UK as lyophilised (freeze-dried) powder and must be reconstituted before laboratory use. Their storage and handling requirements are essentially identical, simplifying logistics for researchers working with both compounds within the same programme.
|
Specification |
TB-500 10mg |
BPC-157 10mg |
|---|---|---|
|
Supplied form |
Lyophilised powder |
Lyophilised powder |
|
Short-term storage |
2–8°C refrigerated |
2–8°C refrigerated |
|
Long-term storage |
-20°C freezer |
-20°C freezer |
|
Reconstitution solvent |
Bacteriostatic water (preferred) |
Bacteriostatic water (preferred) |
|
Dissolution method |
Gentle swirl — do not vortex |
Gentle swirl — do not vortex |
|
Post-reconstitution storage |
-20°C single-use aliquots |
-20°C single-use aliquots |
|
Freeze-thaw cycles |
Avoid — degrades peptide |
Avoid — degrades peptide |
|
Light sensitivity |
Store away from direct light |
Store away from direct light |
For both the TB-500 10mg research peptide and the BPC-157 10mg research peptide, sterile bacteriostatic water is the recommended reconstitution solvent referenced across the majority of published laboratory protocols. Ascend Peptides UK supplies bacteriostatic water for research alongside both peptide compounds, so researchers can source all three from a single trusted UK supplier with same-day dispatch.
Sourcing TB-500 10mg and BPC-157 10mg Research Peptides in the UK
The quality and purity of both compounds directly determine the reliability and reproducibility of your experimental data. For research-grade results, every batch should meet ≥98% HPLC-verified purity with LC-MS molecular identity confirmation C38H68N10O14 for TB-500, C62H98N16O22 for BPC-157. Independent third-party testing, full batch traceability, and lyophilised powder format are recommended quality criteria for any serious research programme.
Ascend Peptides UK supplies both the TB-500 10mg research peptide and the BPC-157 10mg research peptide to all of these standards, with every batch independently tested by Janoshik and a publicly verifiable Certificate of Analysis available before dispatch. As a UK-based recovery research peptide supplier serving independent researchers, private laboratories, and research institutions, we stock both compounds alongside our complete range of high-purity scientific research peptides, all dispatched same day for orders placed before 4 pm, with free shipping on orders over £50.
UK Regulatory Status — Both Compounds
Both the TB-500 10mg research peptide and the BPC-157 10mg research peptide are classified as research chemicals in the United Kingdom. Neither is a licensed medicine, neither is approved for human consumption, and neither may be used in any clinical, veterinary, or diagnostic context outside of properly regulated research frameworks.
Both compounds are listed on the World Anti-Doping Agency (WADA) Prohibited List as substances banned at all times for athletes subject to anti-doping regulations.
Researchers working in sports science or applied physiology must account for this classification when designing any protocols involving human subjects. For any in vivo animal research in the UK, full compliance with the Animals (Scientific Procedures) Act 1986 (ASPA) is mandatory for both compounds requiring valid Home Office licences and institutional ethical approval before any experimental work begins.
Related Research Compounds
Researchers building multi-compound programmes alongside the TB-500 10mg research peptide and BPC-157 10mg research peptide often incorporate additional compounds from complementary categories. Our IGF-1 LR3 1mg research guide covers the growth factor peptide most commonly studied in parallel with recovery research compounds. IGF-1 LR3 operates through the IGF-1 receptor pathway, providing a mechanistically distinct third variable for researchers studying cellular growth and proliferation alongside cytoskeletal or NO pathway effects.
For researchers in metabolic signalling, our AOD-9604 5mg research guide covers a metabolic research peptide frequently incorporated into multi-compound programmes alongside recovery peptides operating through a separate peptide fragment mechanism relevant to metabolic pathway studies.
Frequently Asked Questions — TB-500 10mg vs BPC-157 10mg Research Peptide
Q: What is the difference between TB-500 10mg and BPC-157 10mg research peptides?
A: The core difference is the mechanism. TB-500 10mg binds globular actin, making it the right tool for cytoskeletal and cell migration research. BPC-157 10mg acts through the nitric oxide pathway alongside VEGF and EGF receptor interactions, making it suited to the NO pathway, gut biology, and tendon cell studies. They are structurally unrelated compounds, not interchangeable.
Q: Can TB-500 10mg and BPC-157 10mg be used together in a study?
A: Yes. Because they operate through entirely different pathways, actin dynamics versus nitric oxide signalling, they can function as independent variables within the same experimental protocol. Both should be sourced to ≥98% HPLC-verified purity and handled under identical laboratory conditions.
Q: Which is better for research — TB-500 10mg or BPC-157 10mg?
A: Neither is universally better; it depends on your experimental objective. TB-500 10mg is the correct tool for actin dynamics and cell migration studies. BPC-157 10mg is the correct tool for NO pathway research, gut biology, and tendon or bone cell models. Select based on mechanistic alignment with your protocol.
Q: Is TB-500 10mg the same as Thymosin Beta-4?
A: No. Thymosin Beta-4 is a naturally occurring 43-amino acid protein. The TB-500 10mg research peptide is a shorter, synthetic 7-amino acid fragment, specifically the actin-binding domain (amino acids 17–23). They are related but structurally distinct; results from full-protein studies cannot be directly attributed to the fragment.
Q: Is BPC-157 10mg derived from the stomach?
A: Yes. BPC-157 10mg is derived from a partial sequence of the body protection compound protein found in gastric juice, which is why a significant body of preclinical research has examined it in gut biology and gastric mucosal cell models, an area where TB-500 has no published research presence.
Q: Are TB-500 and BPC-157 research peptides legal in the UK?
A: Yes. Both are legal to purchase in the UK as research chemicals for legitimate laboratory use; neither is a controlled substance. However, both are listed on the WADA Prohibited List and must not be used by athletes. All purchases from Ascend Peptides UK are for laboratory research use only.
Q: What reconstitution solvent should I use for TB-500 10mg and BPC-157 10mg?
A: Sterile bacteriostatic water is the recommended solvent for both compounds. Add it slowly down the inner wall of the vial, gently swirl to dissolve, do not shake or vortex. Aliquot into single-use volumes, store at -20°C, and avoid repeated freeze-thaw cycles.
Q: What purity standard should both compounds meet?
A: Both should meet ≥98% purity confirmed by HPLC, with molecular identity verified by LC-MS. A batch-specific Certificate of Analysis from an independent third-party laboratory is essential. Every batch from Ascend Peptides UK is independently tested by Janoshik with publicly verifiable CoA documentation.
Q: Where can I buy TB-500 10mg and BPC-157 10mg in the UK?
A: Both are available directly from Ascend Peptides UK with same-day dispatch before 4pm, free shipping over £50, and a Janoshik third-party verified Certificate of Analysis on every vial. For laboratory research use only.
Q: Are TB-500 and BPC-157 banned by WADA?
A: Yes. Both are listed on the WADA Prohibited List as non-Specified Substances banned at all times. Enforcement cases for both have resulted in significant ineligibility periods. Researchers in sports science must account for this when designing protocols involving human subjects.
Q: What is the molecular weight of TB-500 vs BPC-157?
A: TB-500 10mg has a molecular weight of 889.02 g/mol (C38H68N10O14, 7 amino acids). BPC-157 10mg has a molecular weight of approximately 1,419.53 g/mol (C62H98N16O22, 15 amino acids). Both should be confirmed by mass spectrometry when sourcing from any supplier.
Conclusion: TB-500 10mg vs BPC-157 10mg Research Peptide
The TB-500 10mg research peptide and the BPC-157 10mg research peptide are both scientifically significant compounds within the recovery research peptide category, supported by substantial preclinical literature and increasingly active research interest across UK and European institutions. But they are not substitutes for one another.
The TB-500 10mg research peptide, with its actin-binding mechanism and cytoskeletal focus, is the appropriate molecular tool for cell migration, cytoskeletal biology, and actin dynamics research.
The BPC-157 10mg research peptide, with its nitric oxide pathway activity and gastric origin, is the appropriate tool for NO signalling, gut biology, tendon cell, and multi-pathway growth factor studies.
For UK researchers and laboratories requiring either or both compounds, Ascend Peptides UK supplies the TB-500 10mg research peptide and the BPC-157 10mg research peptide to ≥98% HPLC-verified purity, independently tested by Janoshik, with same-day UK dispatch and full batch documentation.
DISCLAIMER
All products supplied by Ascend Peptides UK are intended strictly for research purposes only. They are not intended for human consumption or for any therapeutic, diagnostic, or clinical use. None of the items offered are classified as medicinal products by the MHRA. It is the buyer’s responsibility to ensure all purchases comply with applicable laws and regulations. Ascend Peptides UK accepts no liability for misuse.
